Frontlight ResearchEarly access
WithdrawnPhase 1
Evaluation Study of New Compounds With Potential Use in Schizophrenia
Key facts
- Who runs it
- Central Institute of Mental Health, Mannheim
- Where
- Germany1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Phase
- Phase 1
- Started
- 31 Jan 2025
- Ended
- 31 Jan 2025
- Type of study
- Interventional, 3 groups
- Treatments tested
- URB597
- intranasal Insulin
- Cannabidiol CR
- Record updated
- 21 March 2025
- Why it stopped
- Lack of funding
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Healthy volunteers
- Informed consent given by the subject
- Both, female and male subjects may participate
- Age between 18 and 65 years
- Negative drug-screening at the time of screening
- In female participants in fertile age, reliable contraception, which means contraception's pearl-index is equal or smaller than 1
- Non-Smoker
- Body Mass Index between 18 and 40
Who cannot take part
- Consumption of any illegal drugs (except cannabis in history, see above)
- Any current psychiatric disorder through the Structured Clinical Interview for DSM-IV (SCID) at the time of screening
- Any known psychiatric or neurological illness in the participant's history
- Known family history concerning psychiatric disorders
- Severe physical (internal) or neurological illness, especially cardiovascular, renal, advanced respiratory, haematological or endocrinological failures or infectious diseases (acute hepatitis A, B or C or HIV) assessed at the time of the screening by the subject's history, clinical examination and laboratory testing, at the discretion of the investigator
- Lack of accountability
- Relevant use of cannabis (which is defined on the present state of knowledge as at the most five times lifetime-consumption and no consumption for at least one year)
- Pregnancy or lactation phase in female at the time of screening
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Different compounds that might modify the glucose regulation in the central nervous system will be evaluated in healthy volunteers. Several examinations will be performed in order to get a detailed plan how these substances might work.
The 3 groups in the trial
- Intranasal InsulinTreatment being tested
Intranasal administered insulin
- Cannabidiol CRTreatment being tested
Cannabidiol is the main non psychoactive compound of the Cannabis sativa plant.
- URB597Treatment being tested
URB597 is a selective inhibitor of the Fatty acid amide hydrolase enzyme.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation of Potential Central Glucoregulatory Compounds to Treat/Ameliorate the Symptoms of Schizophrenia: a Proof-of-concept Study in Healthy Volunteers.
- Record updated
- 21 March 2025